Synonym
JTS653; JTS 653; JTS-653
IUPAC/Chemical Name
(3S)-3-(Hydroxymethyl)-4-(5-methylpyridin-2-yl)-N-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide
InChi Key
QZUCKCLSVBFSOS-INIZCTEOSA-N
InChi Code
InChI=1S/C23H21F3N4O4/c1-14-5-7-19(27-9-14)30-16(11-31)12-33-21-17(3-2-4-18(21)30)22(32)29-15-6-8-20(28-10-15)34-13-23(24,25)26/h2-10,16,31H,11-13H2,1H3,(H,29,32)/t16-/m0/s1
SMILES Code
O=C(C1=C2OC[C@H](CO)N(C3=NC=C(C)C=C3)C2=CC=C1)NC4=CC=C(OCC(F)(F)F)N=C4
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
474.44
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Kitagawa Y, Tamai I, Hamada Y, Usui K, Wada M, Sakata M, Matsushita M. Orally administered selective TRPV1 antagonist, JTS-653, attenuates chronic pain refractory to non-steroidal anti-inflammatory drugs in rats and mice including post-herpetic pain. J Pharmacol Sci. 2013;122(2):128-37. Epub 2013 Jun 1. PubMed PMID: 23728381.
2: Kitagawa Y, Wada M, Kanehisa T, Miyai A, Usui K, Maekawa M, Sakata M, Matsuo A, Hayashi M, Matsushita M. JTS-653 blocks afferent nerve firing and attenuates bladder overactivity without affecting normal voiding function. J Urol. 2013 Mar;189(3):1137-46. doi: 10.1016/j.juro.2012.09.055. Epub 2012 Oct 8. PubMed PMID: 22999996.
3: Kitagawa Y, Miyai A, Usui K, Hamada Y, Deai K, Wada M, Koga Y, Sakata M, Hayashi M, Tominaga M, Matsushita M. Pharmacological characterization of (3S)-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-N-[6-(2,2,2-trifluoroethoxy)pyrid in-3-yl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide (JTS-653), a novel transient receptor potential vanilloid 1 antagonist. J Pharmacol Exp Ther. 2012 Aug;342(2):520-8. doi: 10.1124/jpet.112.194027. Epub 2012 May 15. PubMed PMID: 22588258.